Physician associate prescribing: perspectives, practices and pathways.

With the introduction of statutory regulation of physician associates (PAs) through the General Medical Council (GMC) expected in 2024, we anticipate a consultation on whether PAs will be given prescribing rights and how this will happen. In anticipation of this consultation, we surveyed the opinions of PAs and healthcare professionals (HCPs) who work with them regarding prescribing rights for PAs. We had a combined response of more than 500 and the survey results show that the vast majority of respondents across the two groups are in favour of prescribing rights for PAs. While both HCPs and PAs overall feel that PAs should have prescribing rights, PAs prefer generalised rights while HCPs recommend specialist rights only. To ensure safe prescribing, we advocate for a safety assessment followed by a period of supervision in their specialty before prescribing rights are given: our data show that confidence, knowledge and safety increases with length of time in specialty. Prescribing rights for PAs will help them become more independent and valuable assets to the healthcare team, increasing efficiency and improving patient care.

Preparing physician associates to prescribe: evidence, educational frameworks and pathways.

There are approximately 2,850 physician associates (PAs) in the UK, and this number is growing. PAs are unable to prescribe due to an absence of statutory regulation and necessary prescribing legislation. While PAs cannot prescribe, they must have an adequate level of pharmacology knowledge to safely manage patients. There is an expectation that this is taught as part of the core syllabus on PA programmes. The Department of Health and Social Care (DHSC) recently announced the introduction of statutory regulation of Medical Associate Professionals (MAPs) that include PAs under the General Medical Council. With the introduction of regulation, PAs may be able to prescribe as part of their role. A working group is considering how this might be achieved in terms of education and supervision requirements, delivery of the training and scope of practice. This paper explores the current approach to delivering pharmacology across UK PA programmes. We evaluate what constitutes acceptable training and assessment, and determine if programmes have the capacity to prepare students for prescribing rights. We compare UK PA programmes with those in the USA, with the V300 Independent/Supplementary Prescribing course and with the Prescribing Safety Assessment examination.

Pharmacology for physician associate programmes: a collaborative, flexible and responsive approach to curriculum design.

There are more than 2,000 physician associates (PAs) in the UK working in general practice and secondary care, and that number is growing. The NHS estimates that there will be over 5,900 PAs in the UK by the end of 2023. Currently, PAs in the UK are unable to prescribe medication due to the absence of statutory regulation and the necessary prescribing legislation. The Department of Health and Social Care, with the support of the four UK governments, recently announced the introduction of statutory regulation of medical associate professionals, which includes PAs. The General Medical Council will be the statutory regulator. A working group is now considering prescribing authority, scope of practice, education training and delivery, and how this will be achieved. At St George's, University of London, we teach applied pharmacology as part of the core curriculum for PAs.

Urinary bladder matrix promotes site appropriate tissue formation following right ventricle outflow tract repair.

The current prevalence and severity of heart defects requiring functional replacement of cardiac tissue pose a serious clinical challenge. Biologic scaffolds are an attractive tissue engineering approach to cardiac repair because they avoid sensitization associated with homograft materials and theoretically possess the potential for growth in similar patterns as surrounding native tissue. Both urinary bladder matrix (UBM) and cardiac ECM (C-ECM) have been previously investigated as scaffolds for cardiac repair with modest success, but have not been compared directly. In other tissue locations, bone marrow derived cells have been shown to play a role in the remodeling process, but this has not been investigated for UBM in the cardiac location, and has never been studied for C-ECM. The objectives of the present study were to compare the effectiveness of an organ-specific C-ECM patch with a commonly used ECM scaffold for myocardial tissue repair of the right ventricle outflow tract (RVOT), and to examine the role of bone marrow derived cells in the remodeling response. A chimeric rat model in which all bone marrow cells express green fluorescent protein (GFP) was generated and used to show the ability of ECM scaffolds derived from the heart and bladder to support cardiac function and cellular growth in the RVOT. The results from this study suggest that urinary bladder matrix may provide a more appropriate substrate for myocardial repair than cardiac derived matrices, as shown by differences in the remodeling responses following implantation, as well as the presence of site appropriate cells and the formation of immature, myocardial tissue.

Preservation of micro-architecture and angiogenic potential in a pulmonary acellular matrix obtained using intermittent intra-tracheal flow of detergent enzymatic treatment.

Tissue engineering of autologous lung tissue aims to become a therapeutic alternative to transplantation. Efforts published so far in creating scaffolds have used harsh decellularization techniques that damage the extracellular matrix (ECM), deplete its components and take up to 5 weeks to perform. The aim of this study was to create a lung natural acellular scaffold using a method that will reduce the time of production and better preserve scaffold architecture and ECM components. Decellularization of rat lungs via the intratracheal route removed most of the nuclear material when compared to the other entry points. An intermittent inflation approach that mimics lung respiration yielded an acellular scaffold in a shorter time with an improved preservation of pulmonary micro-architecture. Electron microscopy demonstrated the maintenance of an intact alveolar network, with no evidence of collapse or tearing. Pulsatile dye injection via the vasculature indicated an intact capillary network in the scaffold. Morphometry analysis demonstrated a significant increase in alveolar fractional volume, with alveolar size analysis confirming that alveolar dimensions were maintained. Biomechanical testing of the scaffolds indicated an increase in resistance and elastance when compared to fresh lungs. Staining and quantification for ECM components showed a presence of collagen, elastin, GAG and laminin. The intratracheal intermittent decellularization methodology could be translated to sheep lungs, demonstrating a preservation of ECM components, alveolar and vascular architecture. Decellularization treatment and methodology preserves lung architecture and ECM whilst reducing the production time to 3 h. Cell seeding and in vivo experiments are necessary to proceed towards clinical translation.